| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10519146 | AMGEN INC | KRAS G12C inhibitors and methods of using the same |
May, 2038
(14 years from now) | |
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(16 years from now) | |
| US11827635 | AMGEN INC | Solid state forms |
May, 2040
(16 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11426404 | AMGEN INC | Dosing of KRAS inhibitor for treatment of cancers |
Sep, 2040
(16 years from now) | |
Lumakras is owned by Amgen Inc.
Lumakras contains Sotorasib.
Lumakras has a total of 4 drug patents out of which 0 drug patents have expired.
Lumakras was authorised for market use on 28 May, 2021.
Lumakras is available in tablet;oral dosage forms.
Lumakras can be used as treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior systemic therapy.
Drug patent challenges can be filed against Lumakras from 28 May, 2025.
The generics of Lumakras are possible to be released after 15 September, 2040.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 28, 2026 |
| Orphan Drug Exclusivity(ODE-352) | May 28, 2028 |
Drugs and Companies using SOTORASIB ingredient
NCE-1 date: 28 May, 2025
Market Authorisation Date: 28 May, 2021
Treatment: Treatment of adult patients with kras g12c-mutated locally advanced or metastatic non-small cell lung cancer (nsclc), as determined by an fda-approved test, who have received at least one prior system...
Dosage: TABLET;ORAL
LUMAKRAS family patents
